Christopher Missling - Jan 2, 2024 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Signature
/s/Christopher Missling
Stock symbol
AVXL
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/12/2024, 08:00 PM
Previous filing
Jun 30, 2023
Next filing
Apr 1, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVXL Stock Option (Right to Buy) Award $0 -125K -50% $0.00 125K Jan 2, 2024 Common Stock 125K $10.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Christopher Missling is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.